Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial.
J Intern Med. 2004 May; 255(5):562-70.JI

Abstract

OBJECTIVES

The purpose of this study was to evaluate the long-term cost-effectiveness of clopidogrel on top of standard therapy (including ASA) in patients with acute coronary syndromes without ST-segment elevation in Sweden.

METHODS AND RESULTS

Incremental cost-effectiveness ratios (ICER) were assessed using a Markov model with transition probabilities estimated from the Swedish hospital discharge and cause of death registers. Patients were assumed to be treated for 1 year, with treatment effects (RR = 0.8) and costs taken from the Clopidogrel in Unstable Angina to prevent Recurrent ischaemic Events Trial. Two scenarios were analysed: with patients similar to those in the trial and with patients similar to those from the register. In the first scenario, the predicted net direct cost was 160 euro and the net total cost -54 euro, which with an incremental survival of 0.12 years give the ICER of 1365 euro per life-year gained from the health care payer perspective (including direct costs) and cost savings from the societal perspective (also including indirect costs). The net costs in the second scenario were 149 euro, giving an ICER of 1009 euro for both perspectives.

CONCLUSIONS

Adding clopidogrel to standard therapy including ASA is cost-effective in the studied setting and compares favourably with other cardiovascular treatment and prevention strategies.

Authors+Show Affiliations

Department of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. peter.lindgren@imm.ki.seNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15078498

Citation

Lindgren, P, et al. "Cost-effectiveness of Clopidogrel in Acute Coronary Syndromes in Sweden: a Long-term Model Based On the CURE Trial." Journal of Internal Medicine, vol. 255, no. 5, 2004, pp. 562-70.
Lindgren P, Jönsson B, Yusuf S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial. J Intern Med. 2004;255(5):562-70.
Lindgren, P., Jönsson, B., & Yusuf, S. (2004). Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial. Journal of Internal Medicine, 255(5), 562-70.
Lindgren P, Jönsson B, Yusuf S. Cost-effectiveness of Clopidogrel in Acute Coronary Syndromes in Sweden: a Long-term Model Based On the CURE Trial. J Intern Med. 2004;255(5):562-70. PubMed PMID: 15078498.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial. AU - Lindgren,P, AU - Jönsson,B, AU - Yusuf,S, PY - 2004/4/14/pubmed PY - 2004/5/20/medline PY - 2004/4/14/entrez SP - 562 EP - 70 JF - Journal of internal medicine JO - J. Intern. Med. VL - 255 IS - 5 N2 - OBJECTIVES: The purpose of this study was to evaluate the long-term cost-effectiveness of clopidogrel on top of standard therapy (including ASA) in patients with acute coronary syndromes without ST-segment elevation in Sweden. METHODS AND RESULTS: Incremental cost-effectiveness ratios (ICER) were assessed using a Markov model with transition probabilities estimated from the Swedish hospital discharge and cause of death registers. Patients were assumed to be treated for 1 year, with treatment effects (RR = 0.8) and costs taken from the Clopidogrel in Unstable Angina to prevent Recurrent ischaemic Events Trial. Two scenarios were analysed: with patients similar to those in the trial and with patients similar to those from the register. In the first scenario, the predicted net direct cost was 160 euro and the net total cost -54 euro, which with an incremental survival of 0.12 years give the ICER of 1365 euro per life-year gained from the health care payer perspective (including direct costs) and cost savings from the societal perspective (also including indirect costs). The net costs in the second scenario were 149 euro, giving an ICER of 1009 euro for both perspectives. CONCLUSIONS: Adding clopidogrel to standard therapy including ASA is cost-effective in the studied setting and compares favourably with other cardiovascular treatment and prevention strategies. SN - 0954-6820 UR - https://www.unboundmedicine.com/medline/citation/15078498/Cost_effectiveness_of_clopidogrel_in_acute_coronary_syndromes_in_Sweden:_a_long_term_model_based_on_the_CURE_trial_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0954-6820&date=2004&volume=255&issue=5&spage=562 DB - PRIME DP - Unbound Medicine ER -